IGF-1 LR3: structure and research limits

Natural IGF-1 and the modified molecule

The reviewed human UniProt record describes IGF-1 as a growth-related signal. It binds to a receiving protein on cells called a receptor. This starts signals inside the cell. The mature hormone has 70 amino-acid units, the small building blocks of proteins.

A 1993 study describes two changes in long R3 IGF-I, also called IGF-1 LR3. A chain of 13 units is added at the starting end. Arginine replaces glutamate at position 3 of the original IGF-1 region. Both names refer to specific amino acids.

The count is 70 + 13 = 83 units. Replacing one unit changes its identity without adding another unit. The position 3 in the name refers to the original region. After the extension, that changed unit sits at position 16 of the combined chain.

These records support the named structures. They do not confirm the contents, purity, or safety of a product using the LR3 name.

Why binding proteins matter

IGF-binding proteins attach to IGF-1 and affect how much is available to cells. A 1993 study examined human skin cells grown in a laboratory. These cells made binding proteins of their own. Long-R3-IGF-I had little affinity for those proteins, meaning it attached less readily.

Researchers measured cell growth after 48 hours. LR3 was approximately 20 times more potent than IGF-1 in that assay. Potency compares how much is needed for a measured response. The number describes those cells and conditions. It cannot predict a person's muscle growth or treatment response.

How strong is the evidence? This is a laboratory finding in cultured human cells. The word human identifies the cells' origin. It does not mean people received LR3 in this study. The retained abstract is the source for this comparison; the full methods were not reviewed.

What the animal study measured

A 1995 study gave female guinea pigs a seven-day infusion of IGF peptides. Infusion means delivery over time. Researchers measured body growth and the weight of several organs. With LR3, some organs weighed more relative to body weight, but overall growth did not increase significantly.

That result separates an organ measurement from whole-body growth. It also shows why the exact outcome matters. A change in one tissue does not establish better strength, recovery, or health. These findings apply to the animals and research conditions described in the abstract.

What the FDA letter says

The U.S. Food and Drug Administration (FDA) named IGF1-LR3 in an April 2020 warning letter to Tailor Made Compounding. FDA said the firm's products made with the listed substances did not meet the cited compounding exemptions. It identified the affected products as unapproved new drugs.

The letter concerns that firm's products and the conditions described at that time. It does not establish that every substance called IGF-1 has the same legal status. It also supplies no evidence that an LR3 product is safe or effective for a person.

How to read an LR3 claim

Start with the molecule named in the paper: natural IGF-1, LR3, or another modified form. Then check whether the work studied cells, animals, or people. Read the actual outcome. Cell growth, organ weight, strength, and a health benefit answer different questions.

The sources here establish LR3's identity and specific laboratory findings. They do not establish a safe human use or a human muscle-building result. For the wider outcome question, read the existing muscle-growth evidence review.